Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Imatinib by Aerami Therapeutics for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
Imatinib is under clinical development by Aerami Therapeutics and currently in Phase I for Interstitial Lung Diseases (Diffuse Parenchymal Lung...